Pulmatrix, Inc.
About Pulmatrix, Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $7.8M
- Net income
- -$5.2M
- Total assets
- $4.1M
- Market cap
- $4.9M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $4.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 21, 2014
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Pulmatrix, Inc..
